Maxy-G34
Source Maxy-G34 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Maxy‑G34 is a novel polyethylene glycol‑linked derivative of human granulocyte colony‑stimulating factor (G‑CSF). Developed as a medical countermeasure, it is designed to stimulate neutrophil production and improve survival after acute radiation exposure. Pre‑clinical work has evaluated its pharmacokinetics, pharmacodynamics and efficacy in rodent models of neutropenia and lethal radiation. Studies in mice and rats have shown that a single injection given one day after irradiation can increase survival at doses far lower than conventional G‑CSF, while in chemotherapy‑induced neutropenia models Maxy‑G34 produced a faster and more sustained rise in circulating neutrophils compared with pegfilgrastim.
Mechanism of Action
Maxy‑G34 is a PEG‑ylated form of recombinant human G‑CSF. By binding to the G‑CSF receptor on hematopoietic progenitor cells, it activates the JAK/STAT signaling cascade, promoting proliferation and differentiation of neutrophil precursors and enhancing survival of mature neutrophils. PEGylation prolongs circulating half‑life and reduces renal clearance, resulting in sustained receptor stimulation after a single dose. The extended exposure is thought to allow a more continuous neutrophil rebound, which is crucial in settings of bone‑marrow suppression such as chemotherapy or radiation injury.
What the Research Shows
Pre‑clinical investigations have compared Maxy‑G34 with existing PEG‑G‑CSF products. In a mouse model of the hematopoietic syndrome of acute radiation syndrome, a single dose of Maxy‑G34 given 24 h after lethal irradiation produced survival rates comparable to a ten‑fold higher dose of the reference G‑CSF, and similar to the approved pegylated product Neulasta, while requiring far fewer administrations. Long‑term follow‑up showed that, despite some differences in progenitor cell markers, Maxy‑G34 did not ameliorate residual bone‑marrow damage in survivors. In rats, both healthy and cyclophosphamide‑induced neutropenic animals received Maxy‑G34 or pegfilgrastim under various schedules. Pharmacokinetic/pharmacodynamic modeling indicated that Maxy‑G34 has lower bioavailability but markedly reduced elimination, resulting in superior suppression of neutropenic episodes compared with pegfilgrastim. The models also suggested optimal timing of administration 48 h after chemotherapy.
Reported Benefits
The main reported advantages of Maxy‑G34 are its prolonged half‑life and enhanced biological activity. In the radiation‑exposure study, a single low dose achieved survival comparable to multiple daily doses of unmodified G‑CSF, simplifying logistics for mass‑casualty scenarios. Rat studies demonstrated a greater reduction in neutropenic episodes than pegfilgrastim, indicating potentially stronger or longer‑lasting neutrophil recovery. Modeling predicts that delayed dosing (≈48 h post‑chemotherapy) may further improve efficacy.
Limitations of the Evidence
All data to date are confined to animal experiments; no human clinical trials have been reported. The mouse study showed no improvement in residual bone‑marrow damage, suggesting limited long‑term regenerative benefit. Pharmacokinetic differences were inferred from modeling rather than direct measurement in patients. Safety, tolerability, optimal dosing and regulatory status remain undefined. Consequently, the translational relevance of the observed survival and neutrophil‑boosting effects is uncertain.
Safety Considerations
The published abstracts do not describe adverse events associated with Maxy‑G34 in the mouse or rat studies. Consequently, the safety profile is unknown beyond the absence of reported toxicity in those pre‑clinical models. Potential concerns typical of G‑CSF agents—such as bone pain, splenomegaly or leukocytosis—have not been evaluated for this PEGylated variant. Until human data are available, no conclusions about tolerability or contraindications can be drawn.
How It Is Administered
In the reported pre‑clinical experiments Maxy‑G34 was administered as a single injectable dose to mice 24 hours after radiation exposure and to rats in various dosing schedules. The formulation is a PEG‑conjugated protein, consistent with subcutaneous injection used for other pegylated G‑CSF products, although the specific route was not detailed in the abstracts.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowTomillero A, Moral MA2008-01-01T00:00:00.000000Z
- Journal ArticleLowChua HL, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleLowScholz M, et al.2009-01-01T00:00:00.000000Z
Frequently Asked Questions
What is Maxy‑G34?
Maxy‑G34 is a polyethylene‑glycol‑linked derivative of recombinant human granulocyte colony‑stimulating factor (G‑CSF) developed as a potential medical countermeasure to stimulate neutrophil production after chemotherapy or radiation exposure.
What pre‑clinical evidence supports its use?
Mouse studies showed that a single low dose given one day after lethal radiation improved survival similarly to much higher doses of standard G‑CSF, while rat studies demonstrated a greater reduction in neutropenic episodes compared with pegfilgrastim, based on pharmacokinetic/pharmacodynamic modeling.
Has Maxy‑G34 been approved for any indication?
No regulatory approval has been reported. All published information concerns pre‑clinical investigations; no human clinical trials or licensing decisions have been disclosed.
How does Maxy‑G34 differ from existing pegylated G‑CSF products?
It is designed with a distinct PEGylation pattern that gives lower bioavailability but markedly slower elimination, resulting in a longer circulating half‑life and, in animal models, superior neutrophil‑recovery efficacy compared with pegfilgrastim (Neulasta).
What are the known safety concerns?
The animal studies did not report specific adverse effects, and the safety profile in humans is unknown. Typical G‑CSF‑related side effects have not been evaluated for Maxy‑G34, so caution is warranted pending clinical data.